Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) Shares Outstanding (Weighted Average) (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Shares Outstanding (Weighted Average) for 2 consecutive years, with $61.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 1.86% to $61.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $61.8 million, a 1.86% increase, with the full-year FY2024 number at $58.4 million, changed N/A from a year prior.
  • Shares Outstanding (Weighted Average) was $61.8 million for Q3 2025 at Pyxis Oncology, up from $61.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $61.8 million in Q3 2025 to a low of $51.3 million in Q1 2024.